- Home
- LIXT vs AIXI Comparison
LIXT vs AIXI Comparison
Compare LIXT & AIXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- AIXI
- Stock Information
- Founded
- LIXT 2005
- AIXI 2001
- Country
- LIXT United States
- AIXI China
- Employees
- LIXT N/A
- AIXI N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- AIXI Computer Software: Prepackaged Software
- Sector
- LIXT Health Care
- AIXI Technology
- Exchange
- LIXT Nasdaq
- AIXI Nasdaq
- Market Cap
- LIXT 20.5M
- AIXI 23.3M
- IPO Year
- LIXT N/A
- AIXI 2023
- Fundamental
- Price
- LIXT $4.35
- AIXI $1.11
- Analyst Decision
- LIXT
- AIXI
- Analyst Count
- LIXT 0
- AIXI 0
- Target Price
- LIXT N/A
- AIXI N/A
- AVG Volume (30 Days)
- LIXT 129.2K
- AIXI 255.1K
- Earning Date
- LIXT 11-07-2025
- AIXI 12-26-2025
- Dividend Yield
- LIXT N/A
- AIXI N/A
- EPS Growth
- LIXT N/A
- AIXI N/A
- EPS
- LIXT N/A
- AIXI N/A
- Revenue
- LIXT N/A
- AIXI $70,314,315.00
- Revenue This Year
- LIXT N/A
- AIXI $26.84
- Revenue Next Year
- LIXT N/A
- AIXI N/A
- P/E Ratio
- LIXT N/A
- AIXI N/A
- Revenue Growth
- LIXT N/A
- AIXI 18.84
- 52 Week Low
- LIXT $0.64
- AIXI $1.08
- 52 Week High
- LIXT $6.26
- AIXI $7.20
- Technical
- Relative Strength Index (RSI)
- LIXT 45.71
- AIXI 39.52
- Support Level
- LIXT $4.05
- AIXI $1.16
- Resistance Level
- LIXT $4.42
- AIXI $1.27
- Average True Range (ATR)
- LIXT 0.40
- AIXI 0.12
- MACD
- LIXT -0.04
- AIXI -0.00
- Stochastic Oscillator
- LIXT 41.51
- AIXI 6.12
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About AIXI XIAO-I Corporation
XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.